Norden Group LLC Trims Stake in Prestige Consumer Healthcare Inc. (NYSE:PBH)

Key Points

• Norden Group LLC sold 5,210 shares of Prestige Consumer Healthcare Inc., reducing its stake by 36.0% in the first quarter, retaining 9,255 shares valued at $796,000.
• Analysts have upgraded Prestige Consumer Healthcare's stock from a “hold” to a “buy” rating, with a consensus price target set at **$93.33**.
• The company's latest earnings report showed a revenue increase of 7.0% year-over-year, with an earnings per share (EPS) of **$1.32**, surpassing estimates by $0.02.

Norden Group LLC lessened its stake in Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) by 36.0% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 9,255 shares of the company's stock after selling 5,210 shares during the period. Norden Group LLC's holdings in Prestige Consumer Healthcare were worth $796,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. Geode Capital Management LLC boosted its stake in shares of Prestige Consumer Healthcare by 1.7% during the 4th quarter. Geode Capital Management LLC now owns 1,348,745 shares of the company's stock worth $105,342,000 after acquiring an additional 21,951 shares during the last quarter. Kayne Anderson Rudnick Investment Management LLC purchased a new position in shares of Prestige Consumer Healthcare during the 4th quarter valued at $84,932,000. Invesco Ltd. lifted its stake in shares of Prestige Consumer Healthcare by 2.4% during the 4th quarter. Invesco Ltd. now owns 1,060,263 shares of the company's stock valued at $82,796,000 after buying an additional 24,392 shares in the last quarter. Congress Asset Management Co. lifted its stake in shares of Prestige Consumer Healthcare by 9.1% during the 1st quarter. Congress Asset Management Co. now owns 991,580 shares of the company's stock valued at $85,246,000 after buying an additional 82,838 shares in the last quarter. Finally, Northern Trust Corp lifted its stake in shares of Prestige Consumer Healthcare by 10.9% during the 4th quarter. Northern Trust Corp now owns 813,076 shares of the company's stock valued at $63,493,000 after buying an additional 80,055 shares in the last quarter. Institutional investors own 99.95% of the company's stock.

Prestige Consumer Healthcare Price Performance

Shares of Prestige Consumer Healthcare stock traded down $1.69 during trading hours on Tuesday, reaching $74.61. The company's stock had a trading volume of 343,104 shares, compared to its average volume of 411,685. The firm has a 50 day moving average price of $81.56 and a 200-day moving average price of $82.39. Prestige Consumer Healthcare Inc. has a one year low of $64.94 and a one year high of $90.04. The company has a debt-to-equity ratio of 0.55, a current ratio of 4.20 and a quick ratio of 2.82. The stock has a market cap of $3.69 billion, a P/E ratio of 17.39, a P/E/G ratio of 2.29 and a beta of 0.43.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported $1.32 earnings per share for the quarter, topping analysts' consensus estimates of $1.30 by $0.02. Prestige Consumer Healthcare had a net margin of 18.86% and a return on equity of 12.87%. The firm had revenue of $296.52 million for the quarter, compared to the consensus estimate of $289.36 million. During the same period in the previous year, the firm posted $1.02 EPS. The business's quarterly revenue was up 7.0% on a year-over-year basis. On average, analysts predict that Prestige Consumer Healthcare Inc. will post 4.5 EPS for the current year.

Analysts Set New Price Targets

A number of research analysts recently weighed in on the stock. Royal Bank Of Canada upgraded shares of Prestige Consumer Healthcare to a "hold" rating in a research note on Thursday, May 8th. Wall Street Zen upgraded shares of Prestige Consumer Healthcare from a "hold" rating to a "buy" rating in a research note on Saturday, July 5th. Three research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $93.33.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.